Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins

CHEMBL6068345 Phase 4 已批准 Cell

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This advanced therapy medicinal product involves harvesting a patient's own cartilage cells, expanding them outside the body, and reimplanting them to repair cartilage defects in the knee. The autologous nature minimizes the risk of immune rejection. It represents a tissue engineering approach to regenerating damaged articular cartilage.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This advanced therapy medicinal product involves harvesting a patient's own cartilage cells, expanding them outside the body, and reimplanting them to repair cartilage defects in the knee. The autologous nature minimizes the risk of immune rejection. It represents a tissue engineering approach to regenerating damaged articular cartilage.

Yes, Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins is an approved drug. It has reached clinical phase 4. It is classified as a Cell.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068345. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.